

# Moventix

#### **Bioventix Presentation: October 2019**

- Bioventix & antibodies for blood testing
- Bioventix portfolio of antibodies and their advantages
- 2018/19 final results and comment
- Research and pipeline development
- Business continuity
- Shareholders & the Board
- Conclusions & outlook

### **Bioventix (Farnham)**





•12 FTEs staff in a Bioventix-owned property





•~£300k investment in a modest expansion and new equipment purchases on-going Q4.2019




Purification and testing

**M**bioventix


#### **Automated Blood Testing**





 Bioventix sells liquid "physical" SMAs and derives royalties from their downstream use





## Why SMAs? (testosterone)

Clinical Chemistry 49, No. 8, 2003

Testosterone Measured by 10 Immunoassays and by Isotope-Dilution Gas Chromatography–Mass Spectrometry in Sera from 116 Men, Women, and Children

Joëlle Taieb,<sup>1</sup> Bruno Mathian,<sup>2</sup> Françoise Millot,<sup>3</sup> Marie-Claude Patricot,<sup>2</sup>

Elisabeth Mathieu,<sup>4</sup> Nicole Queyrel,<sup>5</sup> Isabelle Lacroix,<sup>6</sup> Claude Somma-Delpero,<sup>7</sup> and Philippe Boudou<sup>8\*</sup>

Clinical Chemistry 49:8 1381–1395 (2003)

Endocrinology and Metabolism In 2003, it became clear that testosterone testing for women was inadequate

Immunoassays for Testosterone in Women: Better than a Guess?

Endocrine Abstracts (2008) 16 P631

#### Development of an Elecsys<sup>®</sup> Testosterone II Immunoassay with an improved performance for measurement of testosterone in women

Judit Oldekamp, Klaus Hirzel, Erich Schneider & Dieter Gassner

Roche Diagnostics GmbH, Penzberg, Germany.

Immunoassays for testosterone produce sometimes incorrectly high results in female samples. The reasons of this phenomenon are not fully understood, but interference by cross-reacting substances and inaccurate calibration can be critical. One known endogenous interfering substance is dehydroepiandrosterone sulphate (DHEA-S). Other substances still have to be identified.


An Elecsys<sup>®</sup> Testosterone II assay using a new high affinity sheep monoclonal antibody (<u>Bioventix SMA testo3.6A</u>3) is currently in the development pipeline for the Elecsys and cobas e immunoassay platforms.

 Roche published their prototype assay in 2008 and launched this assay in 2009

It is the Bioventix antibody that made this possible



Editorial



markets in May 2017 and in the US in July 2018

# **M**bioventix

#### **Key Financials**





£ ('000)	Year to 30.6.18	year to 30.6.19	Finncap 2019/20
Sales (excluding £772k back-royalty in 2017/18)	7,979	9,290	10,100
P/(L) before tax (excluding £772k back-royalty in 2018/18)	6,094	6,965	7,660
P/(L) after tax (excluding £772k back-royalty in 2017/18)	5,038	5,861	6,360
P/(L) after tax ( <u>including</u> the £772k as stated in the 2017/18 accounts)	5,663	5,861	6,360
Period-end cash	6,986	6,537	
Total regular dividend per share (p) Split between Spring/Autumn	61 25/36	73 30/43	88 35/53
Special dividend Year dividend total	55 116	47 120	

 Underlying growth in sales of 16%; underlying growth in profits before tax of 14%

•43p/share regular dividend; 47p/share special dividend giving 120p/share total for the year







Diazyme (San Diego) and Boditech (Korea) doing well •Overall growth slightly better than the 5-10% generally expected for the IVD industry  Roll-out of high sensitivity assays slowly gathering pace

 Additional growth expected during 2019/20

+27%

#### **Pipeline Development 2019**



	high	Secretoneurin/SN (CardiNor)	Pollution biomonitoring	
		Amyloid (Pre-Diagnostics)		
↑ In		Cardiac MyC (King's)		
Increasing	medium		Biotin (blocking Abs)	
ng pa			virus (contract)	
otenti			T4 (thyroxine)	
potential value	Low		thyroglobulin (contract)	Cancer
lue			Vitamin (contract)	(contract)
		Low	Medium	high

Increasing probability of success  $\rightarrow$ 

•Further technical progress with SN and amyloid projects





#### **Pollution and Bio-Monitoring**










•Fixed and portable devices are able to monitor NOx & PM2.5 particles derived from combustion processes that pollute air

•The objective of the pollution biomonitoring project is to create a lab-based "ELISA" urine test that would give a measurement of actual individual pollution exposure





 Customers take 2-4 years to: formulate a prototype test; conduct field trials; submit data to regulatory authorities; obtain marketing approval

•This is an impediment to revenue growth – but delivers longer term revenue continuity

# **V**bioventix

### **Selected Shareholder Base**



Institution	Shares (1000s)	%
Sanford DeLand (Castlefield)	985	19.2
Canaccord (Hargreave Hale)	515	10.0
Peter Harrison	428	8.3
Liontrust	395	7.7
Gresham House (Livingbridge)	356	6.9
Jupiter Asset Management	200	3.9
Wasatch Advisors, Inc (Salt Lake City)	151	3.0
Miton Group	149	2.9
Schroder Investment Management	118	2.3
Edentree Investment Management	62	1.2

**Total shares = 5,142,674** 

•From permissions, other available data and TR-1 forms received as at Oct 2019



# **Bioventix Directors**





 Peter Harrison, CEO
>30 years experience of antibody technology at Celltech, KS Biomedix & Bioventix



Ian Nicholson, Chairman

 >30 years experience of commercial development within biotechnology including Amersham, Celltech, Chroma, Clinigen & Consort Medical



•Treena Turner, Finance Director

 Partner at Wise & Co accountants in Farnham.
>10 years experience of Bioventix and accounts preparation



Nick McCooke, Nonexecutive Director

 >30 years experience of biotech industry (including diagnostics R&D) at Celltech, Solexa & Pronota



# **Conclusions and Outlook**



- 2018/19: Another good year of financial results and research pipeline expansion
- 2020-2025: growth linked to initial troponin roll-out and growth in the troponin market through additional troponin applications
- New products emerging from the company's R&D pipeline should be additive in the period 2025-2030

